Home / Transcripts / Ashland Inc. (ASH) · February 3, 2026

Ashland Inc. (ASH) Earnings Call Transcript

February 3, 2026

New York Stock Exchange US Materials Chemicals earnings 80 min

Earnings Call Speaker Segments

Sandy Klugman executive
#1

Thank you. I'm Sandy Klugman, Director of Investor Relations at Ashland. On today's call, I'm joined by Guillermo Novo, our Chair and CEO, William Whitaker, our CFO, and the leaders of our business units: Alessandra Assis, who oversees Life Sciences and Intermediates; James Minicucci, who leads Personal Care; and Dago Caceres, who heads Specialty Additives. Please be aware that slides will be referenced during this call; we invite you to follow along using the webcast materials posted at ashland.com in the Investor Relations section. A reminder that forward-looking statements about our fiscal 2026 outlook and other topics are included in today's presentation, as laid out on Slide 2 and in our Form 10-Q. Risks and uncertainties surrounding these statements could lead to future results that differ materially from the projections shared today; we consider such statements to rest on reasonable assumptions, though we cannot guarantee these expectations will be met. In addition, we'll discuss certain adjusted financial metrics, covering both actual and projected figures, which qualify as non-GAAP measures. These adjusted numbers are presented so you gain further insight into how our ongoing business is performing. Reconciliations to GAAP can be found on our website and in the appendix of these slides. I'll now pass things to Guillermo for his opening remarks.

Guillermo Novo executive
#2

Appreciate that, Sandy, and hello to everybody on the line. Today I'm glad to be with you from Shanghai, China. I'll start by covering the highlights of our first quarter and how our strategic priorities are moving forward. A bit later on this call, I'll come back to discuss some of the newest innovation progress, where we keep seeing enormous momentum and chances to stand apart. William is going to walk through our financial results, how we're executing operationally, and the outlook. Our business unit leaders will add more color on how each of their segments and markets performed. Please go to Slide 5. Let's kick things off by reviewing what drove the business in the first quarter. We posted solid results even as demand stayed soft in coatings and constructions, helped by strong execution and cost discipline. Life Science posted healthy growth, aided by resilient pharma demand and momentum across our Innovate and Globalize pillars. Injectables, tablet coatings, and high-value cellulosic excipients each added to growth versus a year ago. Innovation kept lifting performance, thanks to low nitride cellulosics, high purity excipients, and multiple new product introductions. Personal Care turned in stable performance, with underlying demand largely steady. Biofunctional actives rose double digits, and microbial protection kept picking up share as our Globalize initiatives backed high-value applications. Weaker volumes in core hair and skin care mainly came from isolated, unplanned customer plant outages, against subdued demand. Specialty Additives remained under pressure, with coatings and construction accounting for most of the decline from a year earlier. Coatings weakness showed up most in China and certain export markets, while construction softness mirrored wider market conditions. Even with lower volumes, cost actions and HCC network benefits produced significant margin expansion.

Sandy Klugman executive
#3

Conditions in the intermediate market softened a bit, showing trough-like behavior for BDO and its derivatives, which weighed on captive BDO transfer pricing. On the merchant side, things held steady—volumes were consistent, pricing faced mild pressure, and sales came in flat. From an operations standpoint, the team kept working through equipment replacement at Calvert City while still generating solid free cash flow. While that issue drove up costs and squeezed margins throughout the BPD chain, we kept supplying customers without interruption. What we thought would stay contained in Q1 will now carry over into Q2, because commissioning the new unit uncovered further equipment problems that are pushing back start-up; we expect to finish the needed fixes and get the unit running later in the quarter.

Guillermo Novo executive
#4

Even though it happened beyond Q1, we've also seen effects on our Mid-Atlantic operations from weather-related events that occurred recently. There was no interruption to customer supply, but we do anticipate some added costs, and William will speak to that later on this call when he covers our outlook for the year. Despite the variability we observed from one month to the next, we finished the quarter on stronger footing, as December came in better than November and that momentum has carried into January. All told, these results show steady execution along with continued progress on our strategic priorities. At this point I'll hand the call over to William, who will take you through the first quarter financial performance in greater detail.

William Whitaker executive
#5

Thanks, Guillermo. If you could move to Slide 6. What we saw in the first quarter shows our operating model becoming more and more consistent. Throughout the portfolio, the team performed strongly, pushed our initiatives forward, and worked through operational impacts, all while keeping tight control on costs. The portfolio and manufacturing optimization steps we completed in the prior year continue to bolster margins via better mix, reduced costs, and a leaner footprint. Evoqua appeared in our Q1 results a year ago, yet once we get into Q2, we will have fully anniversaried those portfolio actions, which gives us a clean performance baseline moving ahead and delivered robust operating cash flow. We've also improved how we manage working capital, which the team has been prioritizing. On the whole, the quarter shows a foundation that is getting stronger, with early signals of building momentum, suggesting a growth inflection is taking shape as fiscal 2026 progresses. If you could move to Slide 7. To start, the steadiness of our consumer-facing businesses, which now make up about 85% of our portfolio, keeps delivering significant stability and resilience. Next, our innovation and Globalize initiatives are building solid traction, with momentum holding up in our highest value applications. Third, the structural actions from last year are completely integrated, boosting margin durability and putting us in position for greater leverage once demand rebounds. And last, even in segments facing tougher conditions, our teams stay disciplined and centered on core fundamentals, making sure we remain well-positioned as industry conditions shift. All in all, the quarter shows resilient performance, since our streamlined portfolio, stronger cost structure, and disciplined execution keep supporting our long-term strategy. With innovation picking up speed, Globalize broadening, and productivity initiatives making headway, we are well-positioned to build momentum across the year. And now let's get into the financial details. If you could move to Slide 9. Sales in the quarter came in at $386 million, a decline of 5% compared with last year. The Evoqua divestiture we announced earlier represented approximately $10 million, or around 2% of that decrease. Leaving aside this portfolio action, sales fell 3%, which mirrors a mixed demand environment. Life Sciences kept growing, backed by stable demand and continued innovation momentum. Personal Care is broadly stable and would have posted low single digit growth if not for the unplanned customer outages. Specialty Additives weakened, mirroring wider demand conditions and continued competitive intensity. Pricing moved down 2% broadly across segments, mainly due to carryover adjustments from the previous year. FX added a favorable $9 million, or 2%, to sales compared with the prior year. And now turning to profitability. Adjusted EBITDA reached $58 million, a 5% decline year-over-year, which includes a $1 million impact from the Evoqua divestiture.

Sandy Klugman executive
#6

If you leave out that item, adjusted EBITDA increased 3%, driven by reduced volumes and slight pricing headwinds that were partly countered by positive mix, decreased SARD, and currency tailwinds. It's worth stressing that this quarter carried the $10 million adjusted EBITDA hit we anticipated from the Calvert City outage. As Guillermo pointed out, we originally thought the entire effect would show up in Q1, though a portion will instead spill into Q2, and we'll factor that into our guidance. Raw material costs are still broadly steady to favorable, and our cost initiatives throughout the portfolio keep paying off. Adjusted EBITDA margins came in flat at 15%, with more than 250 basis points of pressure tied to the Calvert City outage. Adjusted operating income was up 27% year over year, which speaks to the underlying business's resilience along with lower depreciation and amortization resulting from our optimization efforts. Adjusted EPS, before intangible amortization, came to $0.26, a 7% decline versus last year on reduced income; we posted a robust quarter for cash generation, with $125 million of cash from operating activities and $26 million of ongoing free cash flow, leaving out the tax refund we previously disclosed. Reduced working capital and CapEx produced solid free cash flow conversion of close to 50% during our seasonally slow quarter. We closed the quarter with roughly $900 million in total liquidity, a sturdy position as we head into the rest of the fiscal year. Net debt stood at $1.1 billion, and net leverage stays healthy at 2.7 times, giving us room to fund strategic priorities while keeping capital allocation disciplined. Let's now hand things to our business unit leaders for a deeper dive into segment results. Alessandra, the floor is yours.

Alessandra Assis executive
#7

Thanks, William. Morning, everyone. If you could go to Slide 10. Over in Life Sciences, revenue came in at $139 million, which is a 4% increase versus the same period a year ago, and that was powered by durable pharma demand along with ongoing momentum in both our Innovate and Globalize pillars. Within pharma, we saw growth in the low single digits compared to last year, and that represents a third straight quarter where volumes improved. Demand for our high-value cellulosic excipients is still robust, backed by wide-ranging customer engagement spanning multiple regions. Injectables posted yet another quarter of significant growth above the market, aided by an expanding pipeline and quicker adoption of products we've launched recently, which strengthens our belief in durable growth for this high-margin segment. Tablet Coatings saw double-digit growth versus a year earlier in every region, with especially powerful momentum throughout Asia Pacific. On the Nutrition side, recent wins along with continuing commercial efforts keep building better traction as we progress through fiscal 2026. On price, we were a bit lower than a year ago, consistent with what we anticipated and mostly a reflection of carryover effects tied to adjustments made in the prior year, though sequentially things held steady. Currency movements gave sales a $3 million lift. Now on innovation, we keep pushing forward with excellence in pharmaceutical ingredients. We benefited meaningfully from our low nitride offering, which includes the recently introduced Plasdome Low Nitride and Benacel Low Nitride Grain. On the injectables front, in October we brought to market our new high-purity viola sucrose stabilizer aimed at biologics. Initial customer interest has been positive, with encouraging technical responses and a commercial pipeline that keeps growing. On top of that, several additional injectable launches are on the docket for fiscal 2026, and each one has solid prelaunch customer engagement behind it plus mounting market pull. These steps forward underscore our dedication to providing high-quality solutions that address changing customer requirements. Moving to profitability, adjusted EBITDA reached $31 million, an 11% gain versus the prior year. Margins widened to 22.3%, which is a 140 basis points improvement, and that figure includes a $4 million hit from the Calvert City outage that occurred during the quarter. The improvement over last year came from favorable mix, durable pharma demand, and reduced SAR as restructuring savings keep coming through, with modest pricing pressure offsetting some of that. Currency movements added another $2 million of benefit to EBITDA. Life Sciences keeps showing solid operational discipline, durable end-market demand, and steady advancement on both our Innovate and Globalize agendas. If you'd turn to Slide 11 for Intermediates. Intermediates' results stayed under pressure, which lines up with what we anticipated as we came into the fiscal year. Revenue was $31 million, a 6% decline from last year. Merchant sales totaled $22 million, with volumes holding steady and mild pricing pressure, which left performance flat versus a year ago. Captive BDO sales fell to $9 million, pulled down by both weaker volumes and reduced transfer prices. Currency movements had almost no effect on sales. On profitability, adjusted EBITDA came to $1 million, a drop from $6 million a year earlier, as margins fell to 3.2% from 18.2%. Margins got squeezed by lower pricing, diminished operating leverage, and about $2 million of early-quarter upstream production effects stemming from the Calvert City outage. The team stays committed to disciplined commercial execution, keeping costs in check, and steering through a market environment that we expect will stay difficult until industrial activity more broadly picks up. At this point, I'll hand things over to Jim so he can talk about Personal Care.

James Minicucci executive
#8

Thanks, Alessandra. Now I'd like to walk through what happened in Personal Care. If you'd go to Slide 12, that covers Personal Care. Our Personal Care business turned in resilient results, which speaks to how steady this portfolio is even when market conditions are mixed. Sales came in at $123 million, an 8% decline versus the same period a year ago, and that drop stems almost completely from the Evoqua divestiture, which took out roughly 7% of sales. Since we've now lapped the Evoqua divestiture, we're working from a clean baseline as we move into Q2. Organic sales were down 1%, which points to a demand environment that's broadly stable. Biofunctional actives keep performing strongly and posted yet another quarter of growth in the double digits compared with the prior year quarter. We're seeing customer expansions and conversions in the project pipeline pick up speed. Colipepto, the hero product we launched in 2025, is seeing wide-ranging adoption across the market. Colipepto mimics 20 collagen sequences found in our skin, delivering immediate flash hydration while correcting how both expression and deep wrinkles appear on the skin. Microbial protection achieved volume growth year-over-year that outpaced the market, thanks to share gains across most regions along with customer wins. Given its competitive and regional footprint, Microbial Protection is positioned well to keep executing against a strong pipeline of opportunities. Performance inside Care Ingredients differed across regions and segments. Broadly speaking, most regions did well, with particularly notable strength in the EMEA region and China. Care Ingredients ran into a number of unplanned customer plant outages during the quarter, plus softer demand in North America. Foreign exchange added about $3 million of favorability to segment sales. For Personal Care, innovation and commercial execution stay a strength, with ongoing momentum across our Globalize platforms and steady demand for higher-value differentiated applications. Moving to profitability, adjusted EBITDA reached $26 million, versus $30 million a year earlier; that figure includes a $1 million EBITDA impact tied to the Evoqua divestiture. Setting aside that portfolio action, EBITDA came in modestly lower, weighed down by the more than $4 million Calvert City impact and the demand trends I mentioned before, partly offset by mix and cost discipline. EBITDA margins held at a healthy 21.1%, which shows the strength of the portfolio and the payoff from our ongoing commercial and productivity efforts. Personal Care keeps delivering strong performance across our Globalize platforms, resilient margins, and meaningful traction in our innovation pipeline. I'll now pass things to Dago, who will review the results for Specialty Additives. Dago?

Dago Caceres executive
#9

Thanks, Jim. If everyone could move to Slide 13. Specialty Additives kept facing soft demand conditions in Q1. Revenue came in at $102 million, a decline of 11% versus the same period last year. The bulk of that year-over-year gap was driven by coatings and construction; within coatings, China was the main drag, as sluggish demand and structural overcapacity kept pressuring the numbers. We also saw additional weakness in export markets across the Middle East, Africa, and India, where competition stayed intense. In North America, coatings demand remained subdued. Beyond those regions, coatings demand held fairly steady, with Europe and Latin America outperforming. Construction volumes also came in lower, mirroring soft conditions throughout the nonstructural repair and remodel market, which is where we have the most exposure. In other industrial end markets, such as energy and performance specialties, demand stayed subdued yet broadly stable. On price, we saw a slight decline versus last year, while foreign exchange added roughly $2 million to sales. The key point is that the team keeps zeroing in on operational efficiency efforts and locking in gains from earlier manufacturing optimization moves, including the HCC consolidation, which strengthens our cost base and helped offset the effect of softer volumes. Adjusted EBITDA reached $15 million, a 15% increase over the prior year. EBITDA margin rose to 14.7%, an expansion of 340 basis points, driven by efficiencies from the consolidated HCC network. The team stays intensely focused on cost control and commercial execution while pushing innovation forward that enables our customers to provide differentiated solutions in a tough market. As evidence of the strength of our innovation pipeline, we generated about $5 million in sales from products launched recently during this quarter. Going forward, Specialty Additives is positioned well to gain from a future coatings rebound, backed by rigorous cost management, a more efficient manufacturing footprint, and continued innovation momentum. With that, I'll turn it back over to William. William?

William Whitaker executive
#10

Appreciate that, Dago. Moving on to Slide 15. I want to highlight what we accomplished in the first quarter under our Execute pillar, and how the operational changes we've been making continue to serve as a foundation for the business. Broadly speaking, we remain on course to hit our goal of about $30 million in total cost savings for fiscal 2026. More specifically, the restructuring plan has been completed and the associated impact will be recognized on a ratable basis throughout the first half of the fiscal year. Our network optimization objectives continue to move forward. The VP and D optimization efforts, along with the small plant consolidation initiative, are likewise proceeding as planned, with the financial benefits expected to be weighted toward the back half. During the prior quarter's discussion, we covered how higher-than-anticipated unit costs at the consolidated HCC site are being addressed while operations scale up. Following the shuttering of Parlane and the rebalancing of network volume, we're now achieving gains in productivity and steadying operations, all while reinforcing the worldwide HCC network. The overall savings goal of $50 to $55 million is unchanged, and there's potential to reach $60 million should demand in China strengthen. Throughout the network, opportunities exist for further productivity gains and capacity optimization. This effort continues, though the direction is favorable. Under Execute, our objectives stay the same: achieve structural cost reductions, streamline the network, and upgrade systems and processes—covering sales and operations planning, standard costing, and forecasting. Every one of those things makes planning stronger, sharpens accountability, and in the end lifts performance. Our operations team deserves credit for steering through a few scattered difficulties during the quarter; those dynamics will get more attention when we cover the outlook. Let's move to Slide 16. At this point I want to bring everyone up to date on our Globalize and Innovate platforms. Looking ahead through fiscal 2026, the momentum both pillars have built early in the year gives me reason for optimism. With Globalize, engagement is up, commercial efforts are well targeted, and our newer investments are starting to pay off — together these are driving dependable traction. So far this year, we've brought in $3 million in incremental Globalize sales, moving us toward the $20 million target we set for the year. Contributions came from across the portfolio, and taken together, the Globalize business lines posted 8% growth compared with last year. On the Innovate side, things moved even faster. We generated $6 million in incremental innovation sales toward our $15 million goal for the year. That shows the ongoing power of our innovation pipeline, especially in pharmaceutics, along with recent commercial launches in several segments. Guillermo will get into more detail on this in a moment, but the team keeps pushing forward a wide and robust launch pipeline. So far, results from Globalize and Innovate are showing just how powerful those two levers are and what a strategic edge they give our portfolio. We're only partway into the year, but we're still positioned to hit the $35 million revenue commitment for fiscal 2026 that comes from Globalize and Innovate. If you'd go to Slide 17, I'll take you through the fiscal 2026 outlook we've updated, which combines a cautious read on the market with ongoing confidence in how we execute. Our adjusted EBITDA range for fiscal 2026 is being narrowed to $400 million to $420 million. Nothing else in our guidance has changed. Let me briefly explain what's driving that outlook. Our Life Sciences and Personal Care segments continue to perform solidly, supported by stable end markets along with momentum coming from our Globalize and Innovate platforms. Within Specialty Additives and Intermediates, conditions remain uneven, and we believe any recovery in coatings will arrive gradually and differ across regions until housing and industrial activity strengthen more broadly. As we move into the early part of the second quarter, demand appears robust in the consumer-facing categories. On the whole, we anticipate raw materials will be stable to favorable, and supply chains remain reliable. Consistent with prior years, we expect performance to be weighted toward the second half. Innovate and Globalize ought to continue growing faster than the markets beneath them, and our goal of $30 million in total cost savings remains on schedule to support better margins as the year goes on. Like Guillermo said, the repairs over at the Calvert City unit are stretching out longer than we'd anticipated. Work we initially expected to wrap up inside the first quarter is now going to spill over into the second. On top of that, we've seen brief site outages these past few weeks thanks to severe weather. Our operations folks kept everything safe and customers weren't disrupted, yet those incidents still created extra expenses and lost operating time. In our revised guidance, you'll see roughly $11 million in one-time effects tied to the delayed start-up at Calvert City along with the weather-driven interruptions we've recently had, and these sit entirely within Q2. The portion linked to volume, which accounted for approximately two-thirds of that figure, is completely recoverable, although the schedule for getting absorption back is more challenging. VP and D won't be able to begin recapturing absorption until that unit is once again operating at standard rates, and that won't occur until the latter part of Q2. So the recovery process can't kick off until Q3, with only some of it flowing through to the income statement by Q4. As for HEC, whether we recover depends on the usual seasonal uptick in demand. Normally, by March we have a clearer picture of what demand will look like from April through September, so right now there's uncertainty around when a recovery can responsibly begin and how big it should be. Because of that timing issue and the seasonal demand patterns we're seeing today, we believe caution is warranted at the upper end of our guidance range. Our approach will continue to be disciplined management of production, inventory, and free cash flow, while ensuring customers receive uninterrupted supply. Taken together, our fiscal 2026 guidance shows balanced planning, disciplined execution, and insight into the factors that drive long-term value creation, even as we navigate temporary operational difficulties; with that, I'll turn the call over to Guillermo to discuss our technology platforms and leadership priorities.

Guillermo Novo executive
#11

Thanks, William. If you could go to Slide 18. At Ashland, innovation continues to be among the strongest engines behind value creation over the long term. And what we're seeing this early in fiscal 2026 is exciting and strategically significant; on this slide you'll see just a handful of the breakthrough platforms that are reshaping our pipeline and creating fresh opportunities across several end markets. These aren't standalone projects. They are scalable technology platforms grounded in science, customer collaboration, and disciplined execution, and each one could drive growth over the long term. Since the 2025 Innovation Day, our teams have made meaningful progress across several platforms. On the TVO side, our technologies continue to advance as we move into early commercial adoption, and that's supported by regulatory filings across every major region plus several rounds of customer qualification. Turning to agriculture, Agramer EcoCoat, which is our TVO designed for seed coatings, received pre-approval from the US EPA during 2025 and also holds REACH approval. Multiple customer trials have confirmed how it performs and its sustainability characteristics, and additional trials remain underway. As for their formulated products, customers are now working through their own regulatory approval submissions in various regions. Alongside that, we're seeing strong momentum in our efforts to develop a TVO aimed at oral dispersions for agricultural formulations. Regulatory clearance is something this product would already possess, just like our Agramer EcoCoat. Over in Personal Care, we introduced Lubrihands, which is a TVO-based offering for conditioning hair, and the response has been terrific — strong feedback from customers, approvals from core customers, plus plenty of additional testing and formulation work. Our TVO development for hairspray and styling applications is coming along nicely and getting close to a generation one launch, with promising customer evaluations now in progress. When it comes to silicone alternatives, our TVO technology has cleared preliminary testing with key customers and has moved into advanced evaluations. On the coatings side, we keep advancing our work on TVO technology aimed at TiO2 efficiency as well as UV curing. Given the performance profiles we're seeing today, every customer is expressing significant interest in these technologies. The bulk of our other fresh TVO development initiatives are still moving forward, and they're showing impressive results along with real value delivered to our customers. Within industrial and specialty coatings, we had yet another successful launch for our super wetting agent platforms, which bring sustainability benefits by avoiding both PFAS and silicone. A newer iteration of Weather EZ Wet 310 was recently brought to market by our coatings team; it carries wider geographic regulatory clearances and is speeding up its path to commercialization. Trials with customers, plus their feedback, have gone well for our new super wetter aimed at agriculture, confirming performance gains without any phytotoxicity when compared with the wetters currently sold commercially. This April, we anticipate getting feedback on our US EPA referral. When it comes to Personal Care, we are pushing this technology further into both hair care and home care uses. When it comes to hair, our current focus is on textured hair, and the feedback from our early beta testing has been quite encouraging. Over in home care, we're pushing forward with super wetter technology designed for auto dishwash uses. Momentum is really picking up in bioresorbable polymers, particularly within aesthetic medicine and next-generation dermal fillers, where launches are set for fiscal year 2025 and recent customer audits back a robust multiyear outlook. Beyond that, we keep expanding a solid pipeline, with preclinical milestone sales across both generic and new drug development programs. In Personal Care, we're also delighted by how people have responded to and performed with our new modified starch, which serves rheology control and skin leave-on applications; this product is set to reach the market this year. Past that, our starch-based technology is expanding into applications for styling hair. Strategically speaking, these platforms carry weight, because every one represents a high-value chance to scale, strengthening our ability to compete and succeed in markets built on differentiation. They demonstrate what happens when our science, global reach, and skill at bringing major new technologies to market combine. Viewed as a group, they make clear why innovation remains a vital driver of growth over the long term. Last, while it does not sit among our new technology platforms, our coatings group is launching multiple new multifunctional HEC products during this year that offer customers unique cost and performance benefits, including reduced expense and easier use alongside enhanced performance. Please turn to Slide 19. Looking forward, I want to lay out the leadership priorities that steer our execution. Though markets are mixed, just as we expected, we head into the year with momentum across multiple areas. The business has grown far more focused, resilient, and better set up to generate high-value growth. Our cost measures are already bolstering margin results, with further P&L gains anticipated as the year goes on. Our innovation platforms and Globalize investments keep building momentum. For fiscal 2026, our objectives are clear. We need to come through on safety, profitable growth, free cash flow, and RONA. We must advance our manufacturing optimization and inventory performance. We should accelerate innovation, grow our Globalize platforms, and build a culture focused on productivity. We'll strengthen our systems and processes, including leveraging AI to improve productivity. We'll prioritize talent development, leadership stability, and organizational strength. And when engaging with our investors, we'll maintain transparent communications and consistent execution. Fiscal 2026 is the year we convert our transformation into sustained performance. Ashland now has a tighter, tougher business mix, a disciplined approach to where capital goes, and a clear plan for where we're headed. Because of that, we're in a strong spot to create lasting value for everyone involved. Even with some short-term operational and weather-related hurdles, our strategy, solid execution, and commercial momentum make us confident we'll hit our fiscal 2026 commitments. I want to thank the entire Ashland team for your hard work and execution, and thanks to all of you for joining today's call. Operator, let's open the line for Q&A.

Josh Spector analyst
#12

Yeah. Hi. Good morning. Two things from me. First, focusing narrowly on Personal Care: could you address those remarks regarding a customer outage that hurt demand? Is this still going on? Has it been fixed? Are we making up the lost ground? Then second, Guillermo, during a few of your prepared comments on last night's release, you mentioned some optimism — I believe about demand you saw building during your second quarter. I'm curious whether you could add more detail on that, if it's contributing to any visibility, or whether things remain fairly limited? Thanks.

Guillermo Novo executive
#13

Okay. I'll make a brief remark about demand, then address the PC outage. Jim, I'll hand it over to you for some input. So we did begin. Looking at Q1, we opened the quarter with strength in November, and I think, much like other companies, November came in a bit softer. After that, we truly saw things pick up in December and January, and as William also noted, growth kept going. So, and it's fairly broad-based. When it comes to Life Science and Personal Care, I'd say coatings is tracking with what we expected. I'm not reading too much into the coating side, since seasonality is still low right now. You know, the season genuinely begins to accelerate in March — really April through September is when larger volume shows up. So it's somewhat early. Still, it's been steady, and I'd say no major surprises. So on the whole, at this moment, we aren't attempting to overread. Nothing really warrants changing our outlook. So we're quite confident; and I think across the next two months, we ought to begin picking up. Our order book for February continues to look strong as well. So we'll watch how that develops. Naturally, we now have, I mean, China, Chinese New Year and all of that. Perhaps it'll be a softer February, but come March, it should improve. Then regarding the PC side, I mean, outages exist; we recently experienced our own outages on certain things; and so those are short-term and recoverable. But, Jim, would you like to weigh in on that?

James Minicucci executive
#14

Appreciate it, Guillermo and Josh. Thanks for asking. So, like William said, if you set aside those customer outages, the business would have grown at a low single-digit rate. To be specific, a number of customers in North America experienced unplanned outages. Those outages happened on the customer's end, so they had nothing to do with any inability on our part to supply, nor were they caused by anything on our side; and from our discussions with customers, we gather that demand wasn't the driver either. Every one of those outages took place in Q1. A few lasted multiple weeks, and a couple ran beyond a month — in one instance, close to two months; all of them are back online now. Each one was back online prior to our closing of Q1. And we do anticipate recovering the bulk of it in Q2 and across the remainder of the year. So some of that recovery is already beginning in Q2. And once we reach the end of the fiscal year, we expect to have recovered the majority of that impact.

Josh Spector analyst
#15

All right. Thanks.

Mike Sison analyst
#16

Hi there. Morning to everyone. Regarding Personal Care, should we expect volumes to begin improving during Q2 or Q3? Is the reason that, as I understand it, Evoqua is finished, correct, when it comes to the guidance? Do we begin to observe growth in volumes that is positive?

Guillermo Novo executive
#17

Yes. So Evoqua is finished, just like Jim mentioned, so because of that the comparisons will be cleaner. You know, if we look simply at the macro on the consumer side, and it's acting resilient on the whole. The majority of our customers are signaling that it's flat at the top. Within the single digits; so from a volume standpoint, we anticipate continuing to see that as the year moves forward; so nothing major surprising there, Mike.

Mike Sison analyst
#18

Great. And then perhaps we could just take another look at the longer-term picture. How are you thinking about getting EBITDA back up to stronger levels from where it stands now?

Guillermo Novo executive
#19

So I'd say, first, a great deal hinges on — well, if you take a look at our strategy, it's Execute, Globalize, Innovate. Execute is all about productivity. We have many projects underway. You know, we're already witnessing the gains. You can see how it plays out in markets and competitive dynamics. Throughout the past year, our margins have kept holding up. And I believe that reflects many of those productivity moves. So that's something we're already doing. Clearly, as volumes recover, you know, we'll gain considerably more leverage when it comes to our absorption and most of our key plans; so a pickup in volume obviously will help a great deal. Right now, we stay focused on pushing that productivity. The majority of the projects are going quite well. I think there was that single plant where we're, you know, devoting a great deal of effort, since all the network trends of the HEC network optimization involve our Hopewell plan. They're extremely busy. There's plenty of activity going on there. When we shut Parlin, they took on a lot of products. Yeah. We've encountered a few cost problems there, so that's the one we'll keep concentrating on. And, clearly, the storm — that was among the locations that got hit the worst. So certain of those initiatives have been delayed somewhat simply because of the storm. But we're focused. We have a clear agenda, and we'll keep driving that. The remainder is going to be the Globalize, Innovate. Every one of those is a higher margin area. And the more we're able to grow, the more we're able to extend, you know, our margins and our EBITDA. And, likewise, I'd say, in Life Science, many of the cellulosic businesses, the growth we're seeing in our core businesses are all higher margin.

William Whitaker executive
#20

And Mike, I'd like to jump in here as well — this is William. Another important element to remember is the program worth $90 million that's still open, correct? That figure combines restructuring along with manufacturing optimization. During fiscal 2025, we captured 25 of it. For fiscal 2026, we've pledged a further 30. Another 35 remains to be realized. So that's the additional piece beyond what Guillermo mentioned regarding productivity. I simply wanted to ensure you're aware of those levers too.

Mike Sison analyst
#21

Understood. Thanks.

John Roberts analyst
#22

Thanks; regarding coatings demand in China, can you see a path to the bottom such that you'll at least start matching flat on a year-over-year basis at some point?

Guillermo Novo executive
#23

Yes. Let me offer a few thoughts, and then I'll turn it to Dago, if you'd like to weigh in. I'm in China at this moment. I'd say a great deal of the effect from the weak market began in the prior year, and it has already occurred. The majority of the effect involving our customers. I don't anticipate things will get better that fast. We observe many moves from the government aimed at stimulating, at reigniting the profit market, but the truth is this will require time. What I think matters here is that muted demand will persist for some period. Given the excess capacity, deflationary pressure will keep appearing everywhere. The bulk of that has already taken place. Our operations here in China have taken a severe hit. So we are reaching a floor. There's a cap on how much. You can shed path. Once a business is gone, nothing more can be lost. So what excites me at present is the team we've rebalanced the network. That way we aren't suffering from idle capacity at our plants. We're relying on a highly cost-efficient plant for us. Now employing it for exports. Across the globe and particularly in The Middle East and Africa; so well-positioned, and today, as I speak with our teams, they've truly accomplished a remarkable job simply by examining our portfolio and using this period to bring our plan costs into line. Yet it's also widening our product line into both more cost-effective, differing performance, the cost parameters so that we're able to compete at the low end. And additionally certain higher performance products that we can deliver with both reduced cost and use yet greater performance. So we're broadening our capacity to re-enter the market in a more constructive manner rather than merely price. Price gains as we go forward. But, Dago, would you like to address the comps and a few of the other items your team is handling?

Dago Caceres executive
#24

Yes, absolutely, Guillermo. I believe your assessment is exactly right. So, looking at China, those comparable figures should become easier during the back half of the year, once we get past the second quarter. That means we're set to run up against the first-quarter figures from a year ago, so we anticipate matching those by the coming quarter. That's the first thing. Another thing I want to stress is this: what exactly are we doing to fix this circumstance? What efforts are underway? There are three items I'd like to highlight. First comes commercial discipline. Second is productivity. Innovation rounds out the three. On commercial discipline, a great deal of attention goes toward managing volume and price, making sure we act in the business's best interest. There's also heavy emphasis on getting close to our customers, remaining tightly connected so we can roll out our innovations. On productivity, the encouraging part is that Nanjing is a truly outstanding facility in our network. It's a highly capable asset, and the team there has very specific goals for boosting productivity that we're pursuing. That makes me quite enthusiastic too. Yet the strongest element is likely innovation. We're acting quickly. We're operating with a sense of urgency. We anticipate that certain outcomes from the innovation work on our main products will show up in 2026. That should genuinely assist us with this circumstance; the goal being to safeguard our main portfolio and then essentially generate create goods designed specifically for the Chinese market. So I'm quite enthusiastic about our efforts here; and finally, I simply want to echo what Guillermo said, which is that this is a truly fine facility. This is a plant I'd describe as, I'd call it an asset on a global scale. Without question. The original plan was to manufacture in China for China, yet this facility is capable of manufacturing for any region worldwide. So what we're doing amounts to rebalancing. There are certainly possibilities beyond China that we're pursuing with great determination.

John Roberts analyst
#25

Then, moving to my second point, which areas carry the greatest exposure and unpredictability for you when it comes to trade matters worldwide?

Guillermo Novo executive
#26

Yes. What we're watching most closely, I'd say, is how Europe will respond. There's considerable pressure being applied to our sector right now, particularly regarding cost competitiveness and the consolidation of plants. A great deal of discussion is taking place on that front. Yet no definitive choices have emerged about their course of action. Still, I'd describe that as likely the main thing we're zeroing in on right now. Nothing stands out to me as concrete, but we recognize this is likely among the spots where pressure runs higher, given regional interests pushing for some kind of move.

John Roberts analyst
#27

Thanks.

Chris Parkinson analyst
#28

Let's revisit Life Sciences for a moment. Now that you've moved past a few years that were somewhat uneven, walk us through the growth algorithm. Stepping back, how do you view it — you never brought up BPND during the PowerPoint, so I'm curious what impact, if any, it had on price mix this quarter. And it does appear you're building some solid momentum in tablets and cellulosics. So as we consider '26 and then, well, '27, is this finally a return to roughly low single-digit volume growth, maybe somewhat better price mix, and margins climbing back to where they were the year before? How should we break that down? Thanks.

Guillermo Novo executive
#29

I'll offer a brief remark, then hand things over to Alessandra. She can provide additional detail and color on the business. But on BPND specifically, I'd say the Life Science business has actually been okay. That's where our problem was. Some time ago — you know the story. A major competitor reentering and all of that. For us, that was the largest problem. It's now stabilized. Correct? So with BPND, I'd describe volumes as steady and pricing as steady. At this moment, it isn't our biggest growth driver. Our goal was to get it stabilized. I believe we're observing that globally. That's among the challenges in truly delivering productivity. Ensuring we stay competitive, and any pricing concession made previously that we're working to recoup via productivity, asset utilization, and similar levers. Still, the team's wider strategy keeps moving forward and honestly never paused, whether in cellulosics or certain other areas. Alessandra, though, if you could weigh in on that and on BPND from your vantage point, that would be great.

Alessandra Assis executive
#30

Right. OK, so as we look forward to the coming quarters, we're anticipating that we'll keep delivering solid growth. There are two pieces to that. First, pharma demand remains resilient at roughly low single digit. Second, we're seeing momentum in both of our pillars, Innovate and Globalize, and that adds about 200 basis points on top of the market for the growth we're forecasting. Like Guillermo said, BPND should be stable; we just finished the contract negotiations in Europe. They largely came in where we expected. There's some modest price pressure in certain portfolios, but on balance, they matched our expectations, so we stay very focused on positioning our Globalize Innovate growth strategy. And the opportunities to gain share. On injectables, we had an outstanding first quarter. Double-digit growth compared to the prior year. We're seeing strong uptake on new — Guillermo discussed this in his prepared remarks on innovation. You're seeing the pipeline expand along with a very effective regional business development model that we've implemented. That positions us to keep seeing sustainable above-market growth in the quarters ahead. On tablet coatings specifically, we also saw double-digit growth. Year over year in the first quarter. The pipeline has grown significantly. And our production efforts were concentrated over the last few quarters, and you're seeing that. We've seen good momentum from a production — from a productivity improvement. In Wilmington and also our new — the new sites in Brazil and China supporting our growth for the fiscal year 2026. And we have a new plant that we announced earlier in India that's coming up in fiscal 2027. So Guillermo was just in India a few days ago, also visiting the new site coming up in fiscal 2027. So overall, a lot of discipline from a commercial standpoint on price volume management and a focus on positioning our Globalize and Innovate growth strategies. Then we are confident in the growth we're projecting over the next couple of quarters.

Chris Parkinson analyst
#31

Understood. As a fast follow-up, tying together a few points you made in response to Josh: within Personal Care there appear to be numerous moving pieces, and it looks as though biofunctionals and bioactives are recovering reasonably well, alongside fresh offerings contributing to NPI momentum. Does that reflect stronger demand in regions such as Asia? A settling down in Europe? Or is it premature to draw that conclusion? I'm attempting to understand the growth rates excluding the problems you encountered in hair care, yet the picture looks fairly encouraging. So I'd be interested in how you view that as we move through fiscal year 26. Thanks.

Guillermo Novo executive
#32

Great. I'll offer a brief remark, and Jim, perhaps you can address the particular regions along with biofunctionals and every one of those areas. But let me clarify one point. When you examine our underlying Personal Care operation — the long-standing business we've operated for quite some time — it's quite steady. The fluctuations mostly stem from what customers require, and there aren't major share movements. Growth, I believe, originates from newer items. Our Globalize sits within both biofunctionals and micro protection; and on the core side, it's all the emerging technologies we're pursuing — and honestly, Personal Care was the very first business where we were actually creating the TVOs and every one of those products. So a degree of stability exists. Many of these things rise and fall. The very same customers who've purchased certain of these items over many years remain, and considerable steadiness is present there. But Jim, would you care to add a bit more color?

James Minicucci executive
#33

Alright, thank you, Guillermo. Hi, Chris. So, I believe we've genuinely been putting in effort to keep the Personal Care narrative as straightforward as we can, considering all the various components and sections of the portfolio. And when we look at Q1, we're quite pleased with it. Like you said, biofunctional did exceptionally well; our base has stabilized, something we discussed during the previous quarter. That base remains steady, and we're actually observing a bit of growth there too; what excites us more is all the effort the team has put into broadening the biofunctional portfolio. We've brought in many new customers, particularly in Europe and China. And we're introducing our new product launches to those customers. As I noted, Colipepto, it's, well, I don't want to call it a miracle product, but it's something where within three minutes, you already begin to feel that hydration. Within a couple of hours, you already start to see real, you know, glowing in your skin, and the team has done an excellent job launching products; and we feel biofunctional is truly heading in the right direction moving forward. Microbial protection, it's entirely about continuing to expand there, converting opportunities, and we've observed really good growth across every region; and then as Guillermo said, in our Care Ingredients business, apart from that, there's always possibly some noise as you approach the end of the year; but we experienced the customer outages specifically in Q1. Typically, it's quite stable. The team has done a really good job converting opportunities, especially in skin. You'll see as we move through the rest of the year oral care will be, I'd say, more smooth this year for us over the next three quarters. Occasionally it tends to be somewhat more concentrated in a couple of quarters. But on the whole, I'd say Q1, really, it was the customer outages; it will be smoother from Q2 to Q4. North America demand that we're continuing to keep an eye on. As I said, a somewhat mixed environment there.

Chris Parkinson analyst
#34

That's useful context, thanks.

Mike Harrison analyst
#35

Hello, and good morning. Alessandra, I had a question — over in Life Sciences, you brought up low nitrate cellulosic. Could you walk us through how those differ from the standard cellulosics, and what makes that distinction matter?

Guillermo Novo executive
#36

Alessandra, maybe you could speak to both the products already introduced and those still rolling out, and not only the cellulosics but the broader high purity initiative your team has underway.

Alessandra Assis executive
#37

Right. So we introduced the new low nitrite grade across both plastones — VP and E — as well as Benacel, the cellulosics, Benecel. What this does is essentially address product quality around nitrosamines in the pharmaceutical sector, relative to what regulators demand. And it's pharma companies broadly, not only the big pharma players but generics too. Every pharma company is heavily concentrated on this — on delivering excipients with a low nitrite grade to assist with nitrosamine levels in their formulations. So the low nitrite launch has been a solid win for us. And we're seeing that grow further as our portfolio extends into additional no-like-type grades — not only some cellulosics, as your question mentioned, but VP and D and other segments as well.

Mike Harrison analyst
#38

All right, that's quite useful. Next, regarding the specialty additives segment, I was hoping you could give a bit more granularity on that $5 million of contribution you expect from innovation. Is it primarily the super wetting agent you mentioned on Slide 18? Or which product lines or technologies are genuinely beginning to demonstrate commercial traction inside specialty additives? Thank you.

Guillermo Novo executive
#39

Yes, thanks for asking. So, yeah, I'd describe it as broad-based; broad-based. So if you examine our approach for specialty additives, it places a major emphasis, naturally, on safeguarding our rheology modifier position, and we've got new products entering that space. Yet there's also a significant push at present to move past this additive toward additional additives. So you've got deformers. You've got wetting agents. You've got pH neutralizers, and so on. And the team has remained quite focused on broadening our portfolio since it genuinely cements the position we hold with customers; it grants us greater access and additionally lets us pursue other portions of our customers' portfolio. As an example, we're extremely strong in architectural coatings. We recognize our customers likewise participate in industrial coatings; it's truly an excellent chance to expand and to genuinely cement our standing there. If you look at the sales and what we're pursuing this year, since we have very solid targets, very robust targets for innovation. Honestly, the emphasis will be on, first, cementing our standing in and distinguishing ourselves in rheology modification. Both synthetic and cellulosic. Second, keep broadening our additives. So you'll see plenty of that, and super wetting agents are part of it. But then strategically and over a longer horizon, very enthusiastic about the headway we're achieving with our platform technologies. Specifically, TVO and TiO2 spacer, and so on, where we do anticipate seeing some traction this year.

Mike Harrison analyst
#40

And Mike, I wanted to draw attention to this. My remarks touched somewhat on regulation—if you observed, regarding many of these innovations, not merely the product and the buyer, but the regulatory dimension. When you introduce novel offerings into today's marketplace, you must navigate all the, you know, authorizations needed to sell such items. In agriculture and reach within Europe. And I believe the coatings group, and that's it. The specialty additives group has performed admirably. The EasyWeb 310. We introduced EasyWeb 300. It performs nicely. Yet because of how it's characterized, we face specific stipulations concerning regulatory demands. So they managed to enter and adjust it sufficiently that performance remained unchanged, but it now enables us to speed up market introduction since it satisfies far more of the regulatory criteria globally; so, you know, planning strategically as we create these offerings and ensuring we stay inside particular boundaries to hasten commercialization. Inside regulatory matters is truly crucial. It appears we've done a quite solid job there. So that release will genuinely assist us in gaining momentum on commercialization. Alright. Many thanks.

Bhavesh Lodaya analyst
#41

Hi. Good morning. This is Bhavesh speaking for John. Just a single question from me. So lately, we observed that an oral dose GLP-1 drug received FDA approval. Could you address whether your life science platform has any exposure to this category involving the oral dose medication, and if so, assist us in considering the potential for demand pull regarding this one. Thank you.

Guillermo Novo executive
#42

Alessandra, would you like to comment on that?

Alessandra Assis executive
#43

Yeah, absolutely. When we consider GLP-1 — that covers both the oral GLP-1 and oral biologics — there's a major opportunity here for Ashland. Our VP and D portfolio is particularly well suited to this area. That means our tablet coatings. Given the high volume and high throughput that these kinds of demand require, our high solids coatings, Aquarius Genesis, are also very well positioned for that. Right now we've got multiple active projects going with some of the largest pharma companies in this space. Beyond that, we're intensifying our innovation efforts here, since we've mapped out a pipeline containing more than 80 emerging opportunities. Among those innovations is our sodium cap rate, a variation enhancer we're aiming to launch during the summer; we've already gotten multiple requests for customer samples and are collaborating with several customers on that upcoming summer launch. So to wrap up, yes, GLP-1 formulations and oral biologics overall represent a major opportunity for Ashland; and our VP and D portfolio is of particular interest, along with our new innovation programs.

Bhavesh Lodaya analyst
#44

Thanks.

David Begleiter analyst
#45

Hello, this is Dave Begleiter. Guillermo, you brought up strengthening momentum in January. Could you discuss that, and also, you have some simpler comparisons in Q2 throughout each of the three segments. So what would that indicate for volume growth in those segments compared with the prior year?

Guillermo Novo executive
#46

Like we stated, it's going to align with what we'd been projecting. So Personal Care and Life Science. That's within the low single digits. Anything beyond that, you know, we'd need to expand via a few of the innovation efforts, though the order book matches our forecast, or our revised forecast, regarding what we're doing. So nothing major unexpected there. Similarly, you know, in the SA, we're observing the same pattern. Every order is arriving as expected. It will remain under pressure versus the previous year due to China. And a few of the factors at play there; yet even North America, Europe truly performed well for us. But I would be I'd simply stay careful. And that's a I won't actually lean positive or negative until we get nearer to the larger season. You know, these months matter less when it comes to how the entire year will turn out; but for us, it's encouraging that January and the February order book stay robust.

David Begleiter analyst
#47

Understood. Regarding those first-half outages, what portion of that $20 million plus comes back to you during the latter six months of the year?

Guillermo Novo executive
#48

We are working — we had intended to begin tackling the initial portion during this quarter, yet clearly that is slipping. The bulk of the problems sat on the BPND side. That was in Q1. That explains why we are exercising somewhat greater caution. Theoretically, every dollar is recoverable. What matters is timing. We aim to recover it; therefore within BPND, as William mentioned, provided we begin at the close of the — and once more, to be clear, we are pushing to finish this as fast as we can. Our expectation is by, you know, the latter portion of the quarter, if we can secure a few — each week matters when it comes to lifting our performance. So we have allowed ourselves some buffer regarding when that unit will come on stream. Yet under our present forecast, it would land at the close of this quarter. That means we, as William mentioned, must capture the majority during Q3 for it to affect this year. Otherwise, should we accomplish it in Q4, we will still recover it, but the benefit shifts into the following year. Thus BPND is a matter of getting that plan underway, after which we can begin realizing recovery of the absorption piece. Additional costs exist. These relate particularly to the storm; they are costs — energy costs that rose, plus other repair costs tied to the freeze. I mean, not massive items, but items that accumulated and will be more of a — I believe it breaks down as one set: two-thirds was absorption, one-third was cost. HEC is a choice. I think they are — I will be candid. I am being quite conservative. Until we begin seeing the season, we can always make more. At any point we choose. I think now is a moment for prudence, as we have practiced in prior years. I am quite open about the balance sheet. It is something we must examine, not merely the P&L. We are not here simply to meet one quarter's results. This is long term. We want to do what is right over the long term for the company. I think maintaining a strong balance sheet — cash is king — during many of these uncertain periods, so we will be somewhat more prudent. Again, a decision. Should the season begin in March, that is likely when we would commence making that; which means, once more, that Q3 would be the pivotal quarter to be built eventually.

David Begleiter analyst
#49

Thanks.

Dan Rizwan analyst
#50

Hello. Dan Rizwan here, filling in for Laurence. I appreciate you taking my question. You brought up injectable launches along with a few of the new products. More broadly, though, I wanted to ask about the timeline — how much time passes before a new product builds up to mid-cycle, and afterward reaches peak sales? Just the general time frame.

Guillermo Novo executive
#51

That genuinely differs depending on which product line you look at. As we've stated previously, though, this covers all of our activities. Our goal is to demonstrate that. Transparency matters a great deal to us. The truth is, once those approvals arrive, they require time. Take the illustration I'd offer — personal care. Suppose customer x gives the green light; that's a major brand. They've got plans, say in 2027, where I'm going to reformulate. Approval happens now, yet the launch occurs in 2027. Or 2026. They hold specific dates. Around which their work is scheduled. So what matters for us is securing those approvals and having all preparations finished ahead of those launch dates; therefore we maintain roadmaps showing when each of these major brands performs reformulations; we collaborate with our customers. Hitting those dates is extremely important. Coatings works somewhat differently; movement there can happen faster, though again, far more testing gets done, additional steps, you know, that's what they prefer. They desire it, yet afterward all of it undergoes some testing; consequently every company follows its own standard. For how they proceed. In my view, pharma involves genuine partnership throughout their whole development, you know, cycle. Thus when launch readiness arrives, you know, you'll accompany them, though that hinges on whether it's a generic. Three to five years could be the span. Should it be a new drug, you know, you're looking at, like, a lengthier pipeline. Yet that's precisely why a robust pipeline matters so much. What we've spent last year doing is constructing that pipeline, and that's what excites me; the technologies have now advanced to the point that they sit within pipelines. Validation is coming our way; so really it's now entering, you know, our customers' thinking that these technologies appeal to them. When will commercialization happen for us? Will it happen next year? So the conversation has shifted considerably. As we continue moving ahead.

Dan Rizwan analyst
#52

Great. Thank you very much.

Eric Boyce analyst
#53

To start, I think there were contract price renewals that happened around the end of the year — could you give us an update on those? And how might the timing of when those renewals take effect shape price by segment in fiscal 2Q and for the rest of the year? Thanks.

Guillermo Novo executive
#54

As Alessandra mentioned, I believe the majority of them are largely finished. In pharma, we're at the final stage. It's mainly in Europe, and that's fairly far along. So I'd say we're largely through there. The only ones — and, Dago, you can weigh in on a few regions — we have some that are still in progress now: Middle East, Africa, India, and those are moving forward in the March, April window. But the rest of them are already complete. Any others on the contract side?

Dago Caceres executive
#55

Not exactly. When it comes to coatings, a number of the bigger agreements—in North America and Europe, I'd say—simply align with the January-to-December period. Those deals are therefore closed, and the outcomes, I believe, came in line with what we anticipated. In other parts of Asia, the agreements actually got wrapped up during October, since their cycle runs from October through October. The only regions still outstanding are the Middle East, Africa, and India, where a few strategic customers are involved, and that timing falls in April. So the contracts have been settled. They take effect beginning in early April. That leaves just that one piece pending. Talks are underway right now, and we anticipate wrapping up a portion of those agreements before long.

Eric Boyce analyst
#56

All right, that's helpful. Now, to build on that, might there be additional divestitures being weighed — perhaps within additives or intermediates — whether at present or in the past? And assuming there aren't, which is my hunch, could you walk us through the reasoning behind why that wouldn't be strategically sound? Thanks.

Guillermo Novo executive
#57

Well, a substantial portion of the restructuring is already behind us. Specifically, we exited those portions of the operation we judged unsuitable, and the bulk of those were standalone pieces. Several product lines that we weren't happy with got consolidated. Selling them wasn't possible, so we retained the asset and found a way to repurpose it. That applied mainly to our CMC asset located in The US along with the MC asset in Europe, and I'd say the timing on that decision worked out quite well. One plant was closed and things were brought together. So every one of those steps has been completed. Additional optimization lies ahead, focused more on productivity — largely involving more units inside the plant that we're streamlining, so that rather than holding lots of equipment that sits underutilized, we can concentrate and put money into the higher-end ones capable of delivering our best cost. That said, none of that would entail a sale. Everything else in the business operates in an integrated fashion. As you're aware, this is the part where everybody just wants it to be live set. The same strategy is being applied across multiple regions. To be honest, based on my past observations at other businesses, breaking everything into artificial segments hasn't produced great results; therefore, we're happy with our current portfolio. It's cohesive. In our view, among the premium pharma, personal care, and architectural coatings, it is indeed taking a hit, yet historically it has leaned more toward consumers. We observe that steadiness across North America and Europe. I'd say the situation in Asia differs somewhat from what we typically see. Those are appealing to us. Our view is that by concentrating on additives — where the cost of use is low and the value derived is high — we can set ourselves apart, while also drawing on the scale our asset base provides. Integration therefore strikes us as essential, and we see genuine worth in artificial.

Eric Boyce analyst
#58

Cool.

Steven Haynes analyst
#59

Morning, and I appreciate you squeezing me in. My question concerns the execute slide you showed. If I'm not mistaken, there's $30 million tied to restructuring, plus further productivity gains that are still marked TBD. Since I've been switching between calls, forgive me if this was covered; could you walk through the schedule, and perhaps how we should frame what that uplift might amount to compared with the cost savings you've already shared and put numbers to for us? Thanks.

Guillermo Novo executive
#60

Guillermo Moreno: We're still working through all of this. We've completed a great deal of network work. Take our acetylene chain, for example, between the two Texas City plants and Copper City — we had units running above their capacity, and that had been the case for quite a while. We consolidated and shut some of them down, moving all our volume onto the units that perform better. That's what's bringing our costs down. Productivity. And as we examined other production units, we're discovering there's room to keep pushing. So again, to give a simple illustration, with core reactors that aren't being fully used, can we focus on just one or two and place our volumes there? Putting money into those reactors gives us higher throughput; cycle times and similar improvements are part of what we're working on. Certain of these efforts are underway already, and we're mapping out how much gain we can achieve. With the rest, we generate the productivity, though the payoff arrives only once pick up happens; the thing is, with productivity, you can't hold off until the volume shows up to act. You go ahead and do it, and when volume eventually arrives, you'll simply be in a position to take advantage of it. Still, it lets us bring cost down while we make some of these changes. That piece is what we're working on figuring out. And clearly, with the storm and everything happening at the moment, our engineers and the rest of the team have had their attention pulled elsewhere for the past few weeks. Even so, the work keeps going. Over the course of this year, we'll be nailing that down. What we intend to do is keep up our current approach and stay fully open about the objectives we plan to take on — letting you know our intentions — after which we'll be answerable for hitting those numbers.

Steven Haynes analyst
#61

Got it. Thanks.

Guillermo Novo executive
#62

So, thanks to all of you for joining this call. We truly appreciate it. We're quite enthusiastic — as you know, the portfolio is going through tough times yet delivering the way we anticipated. Our strategy will keep being pushed forward. That, we feel, is the finest route toward substantial value creation and toward building optionality so we can genuinely advance our profitable growth strategy. So we're eager to meet all of you soon and to have further conversations about Ashland. We appreciate your interest.

Operator operator
#63

Everyone, that wraps up the call for today. We appreciate you joining us. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ashland Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ashland Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.